Technology, not instinct, should guide antibiotic prescribing. A Q&A with Herman Goossens
21/11/2019Quick tests for bacterial infections are out there, but insurers won’t cover them and doctors are reluctant to use them.
Newsroom
Trials@Home project brings clinical trials to the patient
21/11/2019In the future, patients could take part in clinical trials from the comfort of their own home, avoiding the inconvenience of regular clinic visits.
How can we make clinical trials more kid-friendly?
20/11/2019IMI-funded researchers are inviting children and young people to help decide how clinical trials with child participants should be run.
A very promising new antibiotic just started clinical trials
19/11/2019Researchers from ENABLE are hopeful about apramycin because it has passed the stage at which most potential antibiotics fail.
Why it’s so hard to make new antibiotics
15/11/2019There’s no lack of chemicals that can kill bacteria. One of the main reasons there have been so few new antibiotics developed in recent decades – apart from a poor return on investment – is that researchers have run out of ideas on how to outwit the protective mechanisms of Gram-negative bacteria.
For small companies, IMI projects can help tap into new markets
11/11/2019CEO of TRISTAN project partner tells IMI about the opportunities that can open up as a result of getting involved in an IMI project. Karin von Wachenfeldt, Ph. D. is the CEO of Truly Labs, a Swedish SME that carries out preclinical research. Tell us about your company: Truly Labs is a small preclinical CRO (contract research organisation) that provides lab services for drug development. We are based in Lund...
New antibiotics won’t stop antimicrobial resistance. Luckily, there are other things we can try
05/11/2019Vaccines could offer hope - but who to vaccinate, and against what, has no clear answer yet. By Pierre Meulien, Director, IMI
Focus: Antimicrobial resistance
04/11/2019Antimicrobial resistance is becoming one of the defining problems of our time. As bacteria become resistant to the drugs that are supposed to kill them, scientists, policy makers and the pharma industry are looking at different ways to fix the problem before it’s too late. IMI has invested heavily in AMR research. To date, we have invested almost €800 million on 14 projects. In November, we will be taking a...
New IMI project puts immune cells in the spotlight
04/11/2019EUR 27 million Immune-Image project will advance the use of imaging technologies to track immune cells. Immunotherapies, which harness the immune system to fight disease, are revolutionising the treatment of many cancers and inflammatory diseases. However, while these innovative treatments prove life-saving for some patients, others do not respond to immunotherapies at all, and others experience serious side effects. The 5-year Immune-Image project, which started recently, aims to pioneer the...
Trial of second Ebola vaccine to start in Democratic Republic of the Congo
31/10/2019The trial of the two-dose Ebola vaccine regimen aims to help tackle the current outbreak and strengthen future Ebola epidemic preparedness. An international consortium will soon start a large-scale clinical trial of an Ebola vaccine regimen in the Democratic Republic of the Congo (DRC), which is currently experiencing the second worst Ebola epidemic in history. IMI has contributed significantly to the development of the two-dose vaccine regimen, which is manufactured by the Janssen Pharmaceutical Companies of Johnson & Johnson.
Meet IMI at BIO-Europe 2019
29/10/2019In two weeks’ time, IMI will be in Hamburg for BIO-Europe 2019, which runs from 11 to 13 November. A highlight for IMI will be a session on the morning of 12 November on EU support for small and medium-sized enterprises (SMEs). Among the speakers is IMI’s Magali Poinot, who will explain the benefits for SMEs of participating in IMI projects and show how SMEs can get involved in IMI....
Project to team up with African manufacturer to make diagnostic tests
28/10/2019This project is trying out a different kind of capacity building. Apart from hosting workshops and info sessions on the use of VHFMoDRAD's diagnostic tests, the project plans to identify and team up with a Senegalese producer that can make the tests themselves.
Spotlight on early-career investigators: an interview with Benjamin Falcon
23/10/2019Benjamin Falcon is a scientist in the IMPRiND project, which is investigating the role of misfolded proteins in Alzheimer’s and Parkinson’s diseases. Dr Benjamin Falcon is a postdoctoral scientist at the UK Medical Research Council Laboratory of Molecular Biology, working to untangle the mysteries of neurodegenerative conditions such as Alzheimer’s disease. He completed his PhD with Professor Michel Goedert and has developed an impressive track record of findings that progress...
Contribute to the research agenda of the new health PPP
23/10/2019Have your say on the strategic research agenda for a public-private partnership for health innovation under Horizon Europe.
Good data on medication safety for new and expectant mothers is overdue
18/10/2019A survey intends to get a clear picture of women’s experiences of medicating while pregnant or breast-feeding Video: Caroline Swain was five weeks pregnant when she was diagnosed with breast cancer. Her health providers didn't initially know what treatments she could take. © The Pregnancy and Medicines Initiative The problem Evidence suggests that up to 95% of the five million women who get pregnant in the EU every year will...
As Ebola rages in the DRC, the world is closer than ever to the first licensed vaccine
17/10/2019IMI contributed to development of the most promising Ebola vaccines, helping to bring them closer to regulatory approval
Find out about IMI’s future funding opportunities
15/10/2019Cancer, tuberculosis, and psoriasis are among the topics that could be part of our next Call for proposals, IMI2 – Call 20. Also slated for inclusion in the Call are topics on drugs based on proteins, and vaccines.
How do you prepare for a pandemic?
10/10/2019IMI Director Pierre Meulien talks about IMI's reaction to the biggest Ebola outbreak in history and how the world is better prepared for future major epidemics.
EUPATI patient expert training course is open for enrolment
08/10/2019Applications are now being accepted for EUPATI's 14-month training course for laypeople on medicines research and development.
Data-driven personalised care for Alzheimer's patients
07/10/2019EU and industry-funded researchers are testing wearable devices, Internet of Things technologies and smartphone apps to transform the lives of people with Alzheimer's disease.
Focus on: Ebola
03/10/2019During the month of October we will be taking a look at some of the results of our Ebola-related research projects.
Two genes singled out as significant in the development of Alzheimer's
01/10/2019The PHAGO project has identified two genes that might have a significant impact on Alzheimers disease development and progression.
Ebola can now be detected in 15 minutes. Here’s how the diagnostics tests work
30/09/2019IMI backed three bedside Ebola detection tests that work quickly with minimal equipment or training.